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Abstract
Background: The PRESTO study of non-invasive vagus nerve stimulation (nVNS; gammaCore®) featured key primary
and secondary end points recommended by the International Headache Society to provide Class I evidence that for
patients with an episodic migraine, nVNS significantly increases the probability of having mild pain or being pain-
free 2 h post stimulation. Here, we examined additional data from PRESTO to provide further insights into the
practical utility of nVNS by evaluating its ability to consistently deliver clinically meaningful improvements in pain
intensity while reducing the need for rescue medication.
Methods: Patients recorded pain intensity for treated migraine attacks on a 4-point scale. Data were examined to
compare nVNS and sham with regard to the percentage of patients who benefited by at least 1 point in pain
intensity. We also assessed the percentage of attacks that required rescue medication and pain-free rates stratified
by pain intensity at treatment initiation.
Results: A significantly higher percentage of patients who used acute nVNS treatment (n = 120) vs sham (n = 123)
reported a ≥ 1-point decrease in pain intensity at 30 min (nVNS, 32.2%; sham, 18.5%; P = 0.020), 60 min (nVNS, 38.8%;
sham, 24.0%; P = 0.017), and 120 min (nVNS, 46.8%; sham, 26.2%; P = 0.002) after the first attack. Similar significant
results were seen when assessing the benefit in all attacks. The proportion of patients who did not require rescue
medication was significantly higher with nVNS than with sham for the first attack (nVNS, 59.3%; sham, 41.9%; P = 0.013)
and all attacks (nVNS, 52.3%; sham, 37.3%; P = 0.008). When initial pain intensity was mild, the percentage of patients
with no pain after treatment was significantly higher with nVNS than with sham at 60 min (all attacks: nVNS, 37.0%;
sham, 21.2%; P = 0.025) and 120 min (first attack: nVNS, 50.0%; sham, 25.0%; P = 0.018; all attacks: nVNS, 46.7%;
sham, 30.1%; P = 0.037).
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Conclusions: This post hoc analysis demonstrated that acute nVNS treatment quickly and consistently
reduced pain intensity while decreasing rescue medication use. These clinical benefits provide guidance in
the optimal use of nVNS in everyday practice, which can potentially reduce use of acute pharmacologic
medications and their associated adverse events.
Trial registration: ClinicalTrials.gov identifier: NCT02686034.
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Background
Non-invasive vagus nerve stimulation (nVNS; gamma-
Core®; electroCore, Inc., Basking Ridge, NJ, USA) (Fig. 1)
is a safe and effective treatment for patients with mi-
graine [1–4]. The therapy is practical, flexible, and easy
to use, with the lack of drug-drug interactions allowing
its use as a complement to existing treatments [5, 6].
nVNS reduces the need for pharmacologic therapies and
their related side effects in the treatment of migraine [7,
8]. In the PRospectivE Study of nVNS for the acute
Treatment Of migraine (PRESTO), nVNS was superior
to sham for the majority of end points including pain
freedom, pain relief, and ≥ 50% responder rates at vari-
ous time points [4]. Adverse events were minimal and
mostly mild in severity [4]. The PRESTO trial provided
Class I evidence that for patients with an episodic mi-
graine, nVNS significantly increases the probability of
having mild pain or being pain-free 2 h post stimulation.
In this post hoc analysis, we provide further insight
into the practical utility of acute nVNS treatment
through the reporting of clinically relevant end points
that extend beyond the traditional key end points rec-
ommended for pivotal clinical trials by the International
Headache Society (IHS) [9]. The objectives of this ana-
lysis were to evaluate the likelihood of experiencing at
least a 1-point decrease in pain intensity while reducing
the need for rescue medication and to assess whether
treatment of a migraine attack when the pain is mild af-
fects the efficacy of nVNS.
Methods
Study design
The methods for the prospective, double-blind, random-
ized, sham-controlled, multicenter PRESTO study were
previously reported (ClinicalTrials.gov identifier:
NCT02686034) [4]. The study took place at 10 Italian
sites from January 11, 2016, through March 31, 2017,
and consisted of three 4-week periods: 1) run-in, 2)
double-blind, and 3) open-label periods. During the
run-in period, patients received their standard medica-
tions. In the double-blind period, patients were ran-
domly assigned to either nVNS or sham treatment.
During the open-label period, all patients received nVNS
treatment. Patients were instructed to treat up to 5 mi-
graine attacks with nVNS or sham during the
double-blind period and up to 5 additional attacks with
nVNS during the open-label period. Only one attack
could be treated within a 48-h period.
Study population
Patients were 18 to 75 years of age and had a previous
diagnosis of migraine with or without aura according to
the International Classification of Headache Disorders,
3rd edition criteria (ICHD-3) [10]. Key exclusion criteria
included history of secondary headache, another signifi-
cant pain disorder, uncontrolled hypertension, botu-
linum toxin injections in the last 6 months, and head or
neck nerve blocks in the last 2 months.
Intervention
Within 20 min of migraine pain onset, patients
self-administered two bilateral 120-s stimulations (ie, 1
stimulation each to the right and left cervical branch of
the vagus nerve) (Fig. 2). If pain did not decrease 15 min
after nVNS administration, the bilateral stimulations
were repeated. At 120 min, an optional additional set of
stimulations was repeated if the patient was not
pain-free, and optional rescue medication could be used.
Any rescue medication use before the 120-min assess-
ment was considered treatment failure. Patients
Fig. 1 The Non-invasive Vagus Nerve Stimulation Device. Note: A
previous model of the nVNS device was used by patients in the
PRospectivE Study of nVNS for the acute Treatment Of migraine
(PRESTO) trial. Image provided courtesy of electroCore, Inc.
Abbreviation: nVNS, non-invasive vagus nerve stimulation
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maintained preventive migraine medication use at a
stable dose and frequency during the 2 months before
enrollment and throughout the study. No new prevent-
ive medication was permitted during the study.
End points
The percentage of patients with a ≥ 1-point reduction in
pain intensity on a 4-point scale (0, no pain; 1, mild
pain; 2, moderate pain; 3, severe pain) was measured at
30, 60, and 120 min after the first treated attack of the
double-blind and open-label periods. Rescue medication
use and pain-free rates at 30, 60, and 120 min stratified
by initial pain intensity were evaluated for the first
treated attack of both periods. Similar analyses were per-
formed for all attacks for both periods.
Statistical analyses
All analyses were evaluated in the intent-to-treat (ITT)
population, defined as patients who treated at least one
migraine attack in the double-blind period. Proportions
of patients with pain reductions of ≥1 point and propor-
tions of patients who did not use rescue medication
were estimated for the first attack using logistic regres-
sion models adjusted for baseline pain score, preventive
medication use, and presence of aura. P-values for com-
parisons between the nVNS and sham groups were from
the covariate-adjusted logistic regression models.
Pain-free rates for the first attack were presented as pro-
portion and 95% exact binomial confidence interval (CI).
P-values for comparison of pain-free rates for the first
attack between the nVNS and sham groups in the
double-blind period were from the chi-square test or
Fisher exact test, as appropriate. To estimate propor-
tions of all attacks that achieved ≥1-point pain reduc-
tions and proportions of all attacks not requiring rescue
medication, generalized linear mixed-effects regression
models adjusted for baseline pain score, preventive
medication use, and presence of aura were used. Odds
ratios and 95% CIs for comparisons of rates between the
nVNS and sham groups for all attacks were from the
covariate-adjusted generalized linear mixed-effects
regression models; P-values were from resulting F tests.
To estimate pain-free rates for all attacks, unadjusted
generalized linear mixed-effects regression models were
used; P-values comparing nVNS with sham were from
resulting F tests. All data were analyzed using SAS® 9.4
(SAS Institute Inc., Cary, NC, USA).
Results
Patients
Full details on patient disposition, demographics, and
baseline characteristics in the PRESTO study were re-
ported previously [4]. A total of 285 patients with episodic
migraine were enrolled, with 248 randomly assigned to
the nVNS (n = 122) and sham (n = 126) groups. The ITT
population consisted of 120 patients randomized to re-
ceive nVNS and 123 patients randomized to receive sham.
Patients were < 50 years of age at migraine onset, with a
frequency of 3 to 8 attacks per month. Demographic and
baseline characteristics were similar between the nVNS
and sham groups. More patients in the nVNS group than
in the sham group initiated treatment when attack inten-
sity was severe (first attack: nVNS, 23.5%; sham, 15.1%; all
attacks: nVNS, 25.1%; sham, 17.6%). A total of 238 pa-
tients (nVNS, n = 117; sham, n = 121) completed the
open-label period.
≥1-point reduction in pain intensity
Acute nVNS treatment provided clinically meaningful
and significant benefits vs sham in the double-blind
period. For the first treated attack (Fig. 3A), percent-
ages of patients who recorded a ≥ 1-point reduction in
pain intensity were significantly greater in the nVNS
group than in the sham group at 30 min (nVNS, 32.2%;
sham, 18.5%; P = 0.020), 60 min (nVNS, 38.8%; sham,
24.0%; P = 0.017), and 120 min (nVNS, 46.8%; sham,
26.2%; P = 0.002). For all treated attacks (Fig. 3B), sig-
nificantly more ≥1-point pain improvements were seen
with nVNS than with sham at 60 min (nVNS, 33.3%;
sham, 22.2%; P = 0.010) and 120 min (nVNS, 39.4%;
sham, 26.4%; P = 0.006).
Fig. 2 PRESTO Treatment Paradigm. Abbreviations: L, left; nVNS, non-invasive vagus nerve stimulation; R, right; Stim, stimulation
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Percentage of patients not requiring rescue medication
The proportion of patients who did not use rescue
medication was significantly higher with nVNS than
with sham for the first attack (nVNS, 59.3%; sham,
41.9%; P = 0.013) and for all attacks (nVNS, 52.3%; sham,
37.3%; P = 0.008) (Fig. 4).
Pain-free rates by initial pain intensity levels
Differences in pain-free rates between nVNS and sham
were more pronounced in patients who initiated treat-
ment when their attack was mild than for those who
waited until the pain was moderate or severe to treat
their attack. The percentage of patients who success-
fully aborted a mild first migraine attack was signifi-
cantly higher with nVNS than with sham at 120 min
(nVNS, 50.0%; sham, 25.0%; P = 0.018) (Fig. 5A). When
all mild attacks were considered, the percentages that
became pain-free remained significantly higher with
nVNS than with sham at 60 min (nVNS, 37.0%; sham,
21.2%; P = 0.025) and at 120 min (nVNS, 46.7%; sham,
30.1%; P = 0.037) (Fig. 5B). When the initial pain was
severe, the percentage of all treated attacks that were
aborted was significantly higher with nVNS than with
sham at 30 min (nVNS, 4.4%; sham, 0.0%; P < 0.0001)
a
b
Fig. 3 ≥1-Point Reduction in Pain Intensity at 30, 60, and 120 Minutes for (a) First Attack and (b) All Attacks
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(Fig. 5B). The statistical benefit of nVNS vs sham in
treating these severe attacks at 30 min may not be reli-
able given that the sham group had a proportion size of
zero. When the initial pain intensity was moderate or
severe, pain-free rates were not significantly different
between the nVNS group and the sham group, though
they were generally higher in the nVNS group at all
time points.
Clinical utility outcomes in the open-label period
Therapeutic benefits observed in the nVNS group at
120 min during the double-blind period (ie, ≥1-point re-
ductions in pain, decreases in rescue medication use,
and improvements in pain-free rates by initial pain level)
were sustained in the 4-week open-label period during
which all patients received nVNS (Table 1).
Discussion
Treatment with nVNS consistently led to clinically rele-
vant reductions in pain while reducing the need for rescue
medication for the first and all attacks. The ability of
nVNS to offer measurable pain relief for patients without
increasing their exposure to pharmacologic adverse events
or medication overuse provides a practical rationale for its
early use as an acute treatment [11]. Patients who initiated
their treatment when their migraine was mild were more
likely to abort their attacks than those who treated when
their pain was more severe, a finding consistent with
clinical studies that demonstrated the efficacy of pharma-
cologic therapies during early stages of migraine attacks
[12, 13] and when pain was still mild [14–18]. The com-
bination of efficacy and tolerability with nVNS might pro-
vide patients with the confidence to initiate treatment
earlier in their attacks compared with pharmacologic op-
tions that, in clinical experience, are often initiated when
the pain is more severe because of concerns with drug
availability, overuse, and adverse events [14, 19–21].
Findings from mechanistic studies further support the
initiation of nVNS treatment as early as possible to fa-
cilitate greater reductions in pain [22, 23]. Early nVNS
treatment may reduce central excitability by blunting
subsequent neurotransmitter release associated with se-
vere migraine pain [23]. Two additional animal models
demonstrated that nVNS inhibited expression of pro-
teins associated with central sensitization of trigeminal
neurons and reduced susceptibility to cortical spreading
depression [24, 25]. These findings provide the mechan-
istic rationale for optimizing treatment response with
early nVNS administration, before these neurophysio-
logical activities are established.
Migraine may share common mechanistic pathways and
latent causes with comorbid pain disorders such as fibro-
myalgia, chronic pelvic pain, and myofascial pain syndromes
[26, 27]. Consistent with IHS recommendations, the
PRESTO study excluded patients with such disorders al-
though they are frequently seen in clinical practice [4, 9, 26].
Improvements in fibromyalgia symptoms have been ob-
served in patients receiving pharmacologic migraine medi-
cation [26], suggesting that other effective migraine
therapies such as nVNS could also have expanded benefits
for these difficult-to-treat patients. In mechanistic studies,
nVNS was shown to suppress pain markers that are not ne-
cessarily specific to migraine [22–24, 28, 29]. This potential
broader effect on pain is further supported by a
proof-of-concept study of adjunctive implantable VNS for
fibromyalgia, which demonstrated improvement in pain,
overall wellness, and physical function for 5 patients im-
planted with VNS [30]. These mechanistic and clinical in-
sights suggest that evaluation of nVNS as a possible
treatment for patients with migraine and comorbidities such
as fibromyalgia is warranted.
Fig. 4 Rescue Medication Use. Models are adjusted for the patients’ baseline pain score, use of preventive therapies, and presence of aura; data
for number of patients are unadjusted numbers. Abbreviation: nVNS, non-invasive vagus nerve stimulation
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Post hoc analyses of clinical trials can be criticized for
the use of less-rigorous methods or nonrepresentative
subsets of a larger population [31–33]. We performed
these post hoc analyses on the entire study population,
which allowed the identification of a subpopulation of
subjects who were more likely to respond to nVNS (ie,
those who treat the attack when pain is mild). The find-
ings are further strengthened by the analysis of data col-
lected during the observational open-label phase [11].
There are currently no guidelines on the study design of
neuromodulation devices in migraine, and well-controlled
studies must rely only on the recommendations of the
IHS for controlled trials of drugs [9]. These pharmacologic
guidelines may be suboptimal for studies of neuromodula-
tion devices because of the differing mechanisms of action
and interventional targets. Our findings suggest that rigor-
ous post hoc analyses of well-controlled clinical trials
could inform future guidelines for neuromodulation de-
vices. Although the end points in this analysis are not the
previously reported primary or key secondary end points
recommended by the IHS, they provide additional insight
into the practical clinical utility of nVNS in relieving pain
while reducing rescue medication use.
A limiting factor of the PRESTO trial was that the
sham device, which delivered an appreciable electrical
signal, appears to have had some level of vagal activation
[34]. The design of sham devices for neuromodulation
studies is inherently difficult because a compromise
must be reached between maintaining blinding with a
noticeable stimulation and minimizing an active effect.
a
b
Fig. 5 Pain-free Rates at 30, 60, and 120 Minutes for (a) First Attack and (b) All Attacks
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A sham device that produces an active signal could ob-
scure the actual effects of the verum device, thus redu-
cing the opportunity to demonstrate therapeutic benefits
above that of the sham device. We believe that the sham
signal in the PRESTO study likely provided a detectable
degree of active treatment effects that potentially
masked some of the differences between the nVNS and
sham groups in the current analysis [34].
nVNS is a practical treatment option with considerable
clinical utility in the acute treatment of migraine. The like-
lihood that nVNS will quickly reduce pain by at least 1
point and decrease the use of rescue medication highlights
its favorable risk-benefit profile [1–3, 9]. Significant reduc-
tions in the use of acute pharmacologic therapies for the
nVNS group in this analysis may encourage patient confi-
dence and adherence to nVNS as it provides an opportun-
ity to minimize or avoid the potential limitations
associated with traditional acute migraine medications, in-
cluding drug-drug interactions, pharmacologic adverse
events, and medication overuse [35–37]. nVNS offers
flexibility, efficacy, and established safety and tolerability
that may encourage earlier use than is typically seen with
conventional acute therapies. Although demonstrated to
be beneficial, pharmacologic treatments are often reserved
for pain that is more severe because of a range of issues,
including medication-related tolerability and a potentially
insufficient availability of other acute medications [4, 38].
This analysis supports nVNS as a practical and effective
alternative that can be used frequently and as early in an
attack as desired to decrease migraine pain while reducing
the need for rescue medication and minimizing
drug-related adverse events.
Conclusions
These data highlight clinically important benefits of
nVNS as an acute treatment of migraine. nVNS de-
creased pain by at least 1 point while reducing rescue
medication use in most migraine attacks. Unlike most
pharmacologic options, nVNS has the flexibility to be
used alone or as adjunctive therapy for multiple attacks
without risk of pharmacologic interactions and adverse
events. These benefits, along with its convenience and
ease of use, make nVNS an appealing practical option
for the acute treatment of migraine.
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